Tomorrow's rep, tomorrow's market - Pharmaceutical Representative
Saturday, Nov 21, 2009
Search

Tomorrow's rep, tomorrow's market
Tomorrow's rep, tomorrow's market

Pharmaceutical Representative


ROSENTHAL: Reps who face the same managed care hurdles still demonstrate a wide variety of performance results at the end. So even though managed care can set up roadblocks that make it more difficult, you still find reps, regardless of the environment they're in, that outperform people with the same market dynamics.

SNOW: Obviously with single-payer systems in Europe, you still see lots of personal selling. We can take some satisfaction in recognizing that in markets where the margins are lower and the challenges higher, personal selling and conveying information is still an important part of the industry and is seen as valuable by the physicians in those markets.

A version of this article also appears in the February issue of Pharmaceutical Executive.


ADVERTISEMENT

Survey
The more people talk about healthcare reform the less consensus there is, what do you think of current efforts to reform the system?
Healthcare reform is
Good for pharma
Bad for pharma
Doomed to failure
An idea whose time has come
Good for pharma
18%
Bad for pharma
37%
Doomed to failure
24%
An idea whose time has come
21%
GOOGLE ADVERTISEMENTS
Source: Pharmaceutical Representative,
Click here